FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332324963> ?p ?o ?g. }

• W2332324963 endingPage "S181" @default.
• W2332324963 startingPage "S170" @default.
• W2332324963 abstract "The number of recognized fungal pathogens and the alternatives for treatment of infections due to these organisms have increased dramatically in the 1980s. Use of the traditional agent, amphotericin B, has been hampered by severe dose-limiting toxicity and variable efficacy, and flucytosine is characterized by a narrow spectrum, rapid emergence of resistance, and significant dose-limiting toxicities. In recent years, the appearance of a variety of azole antifungal drugs has permitted exploration of the use of different agents in a wide range of dosages for treatment of a variety of fungal infections. Even so, the azoles are often ineffective or cannot be used, and major therapeutic gaps still remain, particularly for patients with AIDS and those with severe neutropenia. For those with acute, life-threatening disease, the use of amphotericin B-lipid complex or ampholiposomes offers the potential of delivering much higher doses of amphotericin B safely. However, the efficacy of these formulations compared with that of amphotericin B is as yet uncertain. In addition to treatment of established disease, there has been interest in using antifungal azoles for prophylaxis for mucocutaneous candidiasis and systemic mycoses in patients who are predisposed to these conditions. Recently completed large-scale studies suggest that antifungal prophylaxis can be accomplished with use of azoles; however, the cost versus benefits of the prophylactic use of these agents is not yet defined. The 1990s will see consolidation of the uses of antifungals presently available, exploration of the use of much higher doses of amphotericin B (perhaps other polyenes as well in liposomal form), and perhaps the use of azoles in combination as well as alone or sequentially in the form of polyene/azole antifungal therapy. New entries may include beta-1,3-glucan inhibitors in the mid-1990s and other classes of drugs toward the end of the decade." @default.
• W2332324963 created "2016-06-24" @default.
• W2332324963 creator A5039293604 @default.
• W2332324963 date "1992-03-01" @default.
• W2332324963 modified "2023-09-25" @default.
• W2332324963 title "Future Directions of Antifungal Chemotherapy" @default.
• W2332324963 cites W1580945072 @default.
• W2332324963 cites W1965088264 @default.
• W2332324963 cites W1970655281 @default.
• W2332324963 cites W1976262029 @default.
• W2332324963 cites W1978737449 @default.
• W2332324963 cites W1988555083 @default.
• W2332324963 cites W1993504788 @default.
• W2332324963 cites W1994352071 @default.
• W2332324963 cites W1994897656 @default.
• W2332324963 cites W1997483245 @default.
• W2332324963 cites W2004532131 @default.
• W2332324963 cites W2007286794 @default.
• W2332324963 cites W2007687804 @default.
• W2332324963 cites W2008293714 @default.
• W2332324963 cites W2019660582 @default.
• W2332324963 cites W2022830148 @default.
• W2332324963 cites W2025804022 @default.
• W2332324963 cites W2032625286 @default.
• W2332324963 cites W2033154566 @default.
• W2332324963 cites W2034848315 @default.
• W2332324963 cites W2036319516 @default.
• W2332324963 cites W2048012191 @default.
• W2332324963 cites W2049442989 @default.
• W2332324963 cites W2049570643 @default.
• W2332324963 cites W2051241295 @default.
• W2332324963 cites W2052469869 @default.
• W2332324963 cites W2056124626 @default.
• W2332324963 cites W2075559398 @default.
• W2332324963 cites W2079310414 @default.
• W2332324963 cites W2079764502 @default.
• W2332324963 cites W2081709709 @default.
• W2332324963 cites W2090630408 @default.
• W2332324963 cites W2103937418 @default.
• W2332324963 cites W2122163712 @default.
• W2332324963 cites W2136395033 @default.
• W2332324963 cites W2138147795 @default.
• W2332324963 cites W2141452876 @default.
• W2332324963 cites W2170512364 @default.
• W2332324963 cites W2312660835 @default.
• W2332324963 cites W2322017308 @default.
• W2332324963 cites W2326510316 @default.
• W2332324963 cites W2330529379 @default.
• W2332324963 cites W2330606664 @default.
• W2332324963 cites W2332111302 @default.
• W2332324963 cites W2923648213 @default.
• W2332324963 cites W74576557 @default.
• W2332324963 doi "https://doi.org/10.1093/clinids/14.supplement_1.s170" @default.
• W2332324963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1562690" @default.
• W2332324963 hasPublicationYear "1992" @default.
• W2332324963 type Work @default.
• W2332324963 sameAs 2332324963 @default.
• W2332324963 citedByCount "72" @default.
• W2332324963 countsByYear W23323249632013 @default.
• W2332324963 countsByYear W23323249632014 @default.
• W2332324963 countsByYear W23323249632015 @default.
• W2332324963 countsByYear W23323249632016 @default.
• W2332324963 countsByYear W23323249632019 @default.
• W2332324963 countsByYear W23323249632020 @default.
• W2332324963 crossrefType "journal-article" @default.
• W2332324963 hasAuthorship W2332324963A5039293604 @default.
• W2332324963 hasConcept C126322002 @default.
• W2332324963 hasConcept C16005928 @default.
• W2332324963 hasConcept C177713679 @default.
• W2332324963 hasConcept C2776694085 @default.
• W2332324963 hasConcept C2777063308 @default.
• W2332324963 hasConcept C2777328456 @default.
• W2332324963 hasConcept C2779548794 @default.
• W2332324963 hasConcept C2779629538 @default.
• W2332324963 hasConcept C2780315139 @default.
• W2332324963 hasConcept C2780651595 @default.
• W2332324963 hasConcept C71924100 @default.
• W2332324963 hasConcept C98274493 @default.
• W2332324963 hasConceptScore W2332324963C126322002 @default.
• W2332324963 hasConceptScore W2332324963C16005928 @default.
• W2332324963 hasConceptScore W2332324963C177713679 @default.
• W2332324963 hasConceptScore W2332324963C2776694085 @default.
• W2332324963 hasConceptScore W2332324963C2777063308 @default.
• W2332324963 hasConceptScore W2332324963C2777328456 @default.
• W2332324963 hasConceptScore W2332324963C2779548794 @default.
• W2332324963 hasConceptScore W2332324963C2779629538 @default.
• W2332324963 hasConceptScore W2332324963C2780315139 @default.
• W2332324963 hasConceptScore W2332324963C2780651595 @default.
• W2332324963 hasConceptScore W2332324963C71924100 @default.
• W2332324963 hasConceptScore W2332324963C98274493 @default.
• W2332324963 hasIssue "Supplement_1" @default.
• W2332324963 hasLocation W23323249631 @default.
• W2332324963 hasLocation W23323249632 @default.
• W2332324963 hasOpenAccess W2332324963 @default.
• W2332324963 hasPrimaryLocation W23323249631 @default.
• W2332324963 hasRelatedWork W1980240355 @default.
• W2332324963 hasRelatedWork W2039708416 @default.
• W2332324963 hasRelatedWork W2140536918 @default.

• next